No Data
Tigermed (300347.SZ): has repurchased 0.42% of shares accumulated.
Glory Capital, January 3rd丨TIGERMED (300347.SZ) announced that as of December 31, 2024, the company's share repurchase special securities account has cumulatively repurchased 3,655,200 shares of the company through centralized bidding trading, accounting for 0.4226% of the company's total share capital and 0.4927% of the company's total A-share capital. The highest Fill Price was 55.30 yuan/share, the lowest Fill Price was 48.17 yuan/share, and the total amount of the transaction was 0.191 billion yuan (excluding trading costs).
FRONTAGE (01521.HK) was increased shareholding by Hongkong Tigermed Co., Limited by 1.064 million shares.
On January 3, Glory Holdings reported that according to the latest equity disclosure data from the Stock Exchange, on December 31, 2024, FRONTAGE (01521.HK) was increased by Hongkong Tigermed Co., Limited in the market, acquiring 1.064 million shares at an average price of HKD 1.773 per share, involving approximately HKD 1.1865 million. After the shareholding increase, the latest number of shares held by Hongkong Tigermed Co., Limited is 1,079,664,090 shares, with the shareholding ratio rising from 52.98% to 53.04%.
Hong Kong stocks are moving | CRO Concept stocks rose broadly in the morning, with most companies' overseas Business improving on a quarter-on-quarter basis. Institutions are Bullish on the Industry entering a stable growth phase.
CRO Concept stocks generally rose in the morning. As of the time of writing, Asymchem Laboratories (06821) rose by 4.16%, trading at 52.6 Hong Kong dollars; WUXI APPTEC (02359) rose by 3.53%, trading at 55.8 Hong Kong dollars; PHARMARON (03759) rose by 3.06%, trading at 14.14 Hong Kong dollars.
Does Hangzhou Tigermed Consulting (SZSE:300347) Have A Healthy Balance Sheet?
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
TIGERMED (03347) provides guarantees for Other holding subsidiaries.
TIGERMED (03347) issued an announcement that the company's controlling subsidiary HeYa Medical Technology (Shanghai) Co., Ltd. (hereinafter referred to as...)
